| Type | Aktiengesellschaft |
|---|---|
| Traded as | SIX: LONN |
| Industry | Chemicals, biotechnology |
| Founded | 1897 |
| Headquarters | Basel, Switzerland |
| Key people | Stefan Borgas (CEO), Rolf Soiron (Chairman) |
| Products | Biopharmaceuticals, organic and fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products |
| Revenue | CHF 2.680 billion (2010)[1] |
| Operating income | CHF 374 million (2010)[1] |
| Profit | CHF 291 million (2010)[1] |
| Total assets | CHF 4.778 billion (end 2010)[1] |
| Total equity | CHF 2.387 billion (end 2010)[1] |
| Employees | 8,280 (2010)[1] |
| Website | www.lonza.com |
Lonza Group is a Swiss chemicals and biotechnology company, headquartered in Basel. The firm provides a number of products and services to the pharmaceutical and life science industries, including organic fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities and chemicals, detection systems and services for the bioscience sector.
Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange. The company has expanded in the United States and acquired smaller biopharmaceutical units in recent years. In October 2011, Lonza acquired American firm Arch Chemicals for $1.4 billion, as a result becoming the world's largest manufacturer of biocides.[2]